Deepalakshmi Kaliyaperumal1, Karthikeyan Rk2, Murali Alagesan3, Sudha Ramalingam4. 1. Physiology, PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu, India. 2. Respiratory Medicine, PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu, India. 3. Internal Medicine, PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu, India. 4. Research and Innovation, PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu, India.
Abstract
OBJECTIVES: The novel corona virus disease, which was initially reported in China in late 2019, has become a global pandemic affecting 330 million cases. COVID-19 affects predominantly the respiratory system, in addition to other organ systems, mainly the cardiovascular system. One of the hypotheses is that virus entering the target cells by binding to angiotensin converting enzyme 2 affecting hypothalamic pituitary axis could lead to dysautonomia which is measured by heart rate variability (HRV). HRV is a non-invasive measure of autonomic function that facilitates identification of COVID-19 patients at the risk of developing cardiovascular complications. So, we aimed to assess HRV in COVID patients and compare between COVID patients and normal controls. METHODS: In a case control design, we compared 63 COVID-19 infected patients with 43 healthy controls matched for age and gender. Along with clinical characterization, heart rate variability was evaluated using ambulatory 5 min ECG in lead II and expressed in frequency and time domain measures. Statistical analysis was performed using SPSS 17.0. RESULTS: Mean age of the study population was 49.1 ± 14.2 years and 71 (66.9%) were males. Frequency domain measures high (HF) and low (LF) frequency powers were significantly decreased in COVID-19 patients compared to controls. HF/LF and LF/HF ratios were not different between groups. Time domain measures rMSSD (root mean square of successive RR interval differences) and SDNN (standard deviation of NN intervals) were significantly increased among COVID-19 subjects. COVID-19 infection was associated with increased parasympathetic activity as defined by rMSSD>40 {adjusted odds ratio 7.609 (95% CI 1.61-35.94); p=0.01} and SDNN>60 {adjusted odds ratio 2.620 (95% CI 1.070-6.44); p=0.035} after adjusting for age, gender and comorbidities. CONCLUSIONS: Our study results showed increased parasympathetic tone in COVID patients. Early diagnosis of autonomic imbalance in COVID patients is needed to plan management and limit progression of disease.
OBJECTIVES: The novel corona virus disease, which was initially reported in China in late 2019, has become a global pandemic affecting 330 million cases. COVID-19 affects predominantly the respiratory system, in addition to other organ systems, mainly the cardiovascular system. One of the hypotheses is that virus entering the target cells by binding to angiotensin converting enzyme 2 affecting hypothalamic pituitary axis could lead to dysautonomia which is measured by heart rate variability (HRV). HRV is a non-invasive measure of autonomic function that facilitates identification of COVID-19patients at the risk of developing cardiovascular complications. So, we aimed to assess HRV in COVIDpatients and compare between COVIDpatients and normal controls. METHODS: In a case control design, we compared 63 COVID-19infectedpatients with 43 healthy controls matched for age and gender. Along with clinical characterization, heart rate variability was evaluated using ambulatory 5 min ECG in lead II and expressed in frequency and time domain measures. Statistical analysis was performed using SPSS 17.0. RESULTS: Mean age of the study population was 49.1 ± 14.2 years and 71 (66.9%) were males. Frequency domain measures high (HF) and low (LF) frequency powers were significantly decreased in COVID-19patients compared to controls. HF/LF and LF/HF ratios were not different between groups. Time domain measures rMSSD (root mean square of successive RR interval differences) and SDNN (standard deviation of NN intervals) were significantly increased among COVID-19 subjects. COVID-19infection was associated with increased parasympathetic activity as defined by rMSSD>40 {adjusted odds ratio 7.609 (95% CI 1.61-35.94); p=0.01} and SDNN>60 {adjusted odds ratio 2.620 (95% CI 1.070-6.44); p=0.035} after adjusting for age, gender and comorbidities. CONCLUSIONS: Our study results showed increased parasympathetic tone in COVIDpatients. Early diagnosis of autonomic imbalance in COVIDpatients is needed to plan management and limit progression of disease.
Authors: Véronique Deschodt-Arsac; Valérie Berger; Leila Khlouf; Laurent M Arsac Journal: Int J Environ Res Public Health Date: 2022-02-02 Impact factor: 3.390
Authors: Gulfidan Bitirgen; Celalettin Korkmaz; Adil Zamani; Mehmet Sinan Iyisoy; Hurkan Kerimoglu; Rayaz A Malik Journal: Int Ophthalmol Date: 2022-04-05 Impact factor: 2.029
Authors: Karina Carvalho Marques; Camilla Costa Silva; Steffany da Silva Trindade; Márcio Clementino de Souza Santos; Rodrigo Santiago Barbosa Rocha; Pedro Fernando da Costa Vasconcelos; Juarez Antônio Simões Quaresma; Luiz Fábio Magno Falcão Journal: Front Cardiovasc Med Date: 2022-04-29